Basilea Pharmaceutica has entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority ...

Initial funding of USD 29 million to support development of Basilea's clinical stage first-in-class antifungals, fosmanogepix a ...

Initial funding of USD 29 million to support development of Basilea's clinical stage first-in-class antifungals, fosmanogepix and BAL2062 -- ...

Expands available market to include over 200 children’s hospitals in the United StatesLEXINGTON, Mass., Sept. 16, 2024 (GLOBE ...

Without immediate action, humanity will face a potentially disastrous escalation in resistance in fungal disease, a renowned ...

How Big is The Saudi Arabia Invasive Fungal Infection Market ?

Rezafungin acetate is under clinical development by Napp Pharmaceuticals and currently in Phase III for Aspergillosis.

An invasive species is an organism that is "non-native (or alien) to the ecosystem under consideration," and whose introduction "causes or is likely to cause economic or environmental harm or harm ...

T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today provided an update on its new product development ...

Invasive fungal infections (IFIs) represent a serious and often overlooked threat to human health. These systemic infections occur when fungi, typically present in the environment, establish ...

Initial funding of USD 29 million to support development of Basilea's clinical stage first-in-class antifungals, fosmanogepix and BAL2062Multi-year Other Transaction Agreement (OTA) allows for potenti ...